In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CinCor Pharma, Inc.

Latest From CinCor Pharma, Inc.

CinFina Pushes Early Work In Obesity In Hopes Of A Deal

Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.

StartUps and SMEs Metabolic Disorders

The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest

Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.

Deals M & A

AZ And Boehringer Move Into Phase III With Rival Next-Gen CKD Drugs

Boehringer Ingelheim and AstraZeneca are once again going up against each other in chronic kidney disease, with Phase II results for their rival new agents showing promise. Unfortunately, they both also lie in the path of Novo Nordisk’s cardiometabolic juggernaut, Ozempic.

Clinical Trials Companies

With Strong Anti-Inflammatory Candidate In Hand, Abivax Execs Carve A Path Forward

With a strong late-stage anti-inflammatory molecule in its pipeline, the challenge for Abivax is to garner the funds to take its obefazimod program forward. To that end, the company is continuing to do a major overhaul of personnel and is sharpening its corporate vision.

Growth Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals